Arovella Therapeutics Company Description

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally.

The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors.

The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021.

Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.

Arovella Therapeutics Limited

Country	Australia
Founded	1999
Industry	Biotechnology
Sector	Healthcare
Employees	27
CEO	Michael Baker

Contact Details

Address: Corporate One Preston, Western Australia 3072 Australia
Phone	61 3 9863 6472
Website	arovella.com

Stock Details

Ticker Symbol	ALA
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU0000182784
SIC Code	3841

Key Executives

Name	Position
Dr. Michael Baker	Chief Executive Officer, MD and Director
Dr. Nicole van der Weerden B.Sc., BSc (Hons), MBA (MBS), Ph.D.	Chief Operating Officer
Timothy Luscombe B.Com., C.A.	Company Secretary and Chief Financial Officer
Michelle Long	Administration Manager